— Know what they know.
Not Investment Advice
Also trades as: NGLFINE.BO (BSE) · $vol 0M

NGLFINE.NS NSE

NGL Fine-Chem Limited
1W: +1.0% 1M: +10.0% 3M: -8.8% YTD: +31.9% 1Y: +121.2% 3Y: +45.9%
₹2,900.00 ($30.11)
-9.50 (-0.33%)
 
NSE · Healthcare · Drug Manufacturers - General · Tech Score Buy · Power 68 · ₹17.9B mcap · 2M float · 1.07% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap₹17.9B ($186.0M)
52W Range1271-3602
Volume15,248
Avg Volume17,760
Beta0.88
Dividend₹1.75
Analyst Ratings
No analyst coverage
Company Info
CEORahul Jayant Nachane
Employees502
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date2022-07-08
301, E Square
Mumbai, MA 400057
IN
91 22 4084 2222
About NGL Fine-Chem Limited

Headquartered in Mumbai, India, and established in 1981, NGL Fine-Chem Limited operates as a worldwide producer and distributor of pharmaceutical ingredients and intermediates for both veterinary and human health sectors. The company's comprehensive portfolio of active pharmaceutical ingredients (APIs) for animal applications features substances like diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin. For human therapeutic use, they supply APIs including nitazoxanide, atovaquone, and ranolazine. Furthermore, NGL Fine-Chem manufactures various intermediate compounds and offers completed pharmaceutical formulations in both granule and tablet formats.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms